转移性NSCLC免疫治疗应答模式:RECIST 1.1、irRECIST与iRECIST比较
该单中心回顾性研究纳入160例接受PD-1或PD-L1抑制剂治疗的晚期NSCLC患者,比较RECIST 1.1、irRECIST和iRECIST对非典型应答的识别。非典型应答发生率为13%,包括假性进展5%和分离应答8%;RECIST 1.1在11%的进展患者中低估了免疫治疗获益,irRECIST与iRECIST仅3.8%不匹配。
要点
- 免疫治疗中非典型应答(假性进展/分离应答)发生率为13%。
- RECIST 1.1在11%的进展患者中低估了免疫治疗获益。
- irRECIST与iRECIST识别非常规应答,不匹配率仅3.8%。
核心结论
- 非典型应答(假性进展/分离应答)在免疫检查点抑制剂治疗的NSCLC中发生率为13%,RECIST 1.1在11%的进展患者中低估了获益。
- irRECIST和iRECIST可识别这些非常规应答,两者间不匹配率为3.8%。
主要发现
- 20例(13%)出现非典型应答,包括8例假性进展(5%)和12例分离应答(8%),其中13例临床获益。
- 按RECIST 1.1,37例(23%)为客观缓解或疾病稳定,123例(77%)为进展。
- 假性进展或分离应答患者的总生存期高于真性进展患者。
关键数值与推荐
- RECIST 1.1评估:23%为客观缓解或疾病稳定,77%为进展。
- RECIST 1.1在11%的进展患者中低估免疫治疗获益。
临床怎么用
- 对免疫治疗中出现的非典型应答模式应警惕假性进展或分离应答,避免过早停用免疫治疗。
- 在进展患者中可考虑结合irRECIST或iRECIST评估以识别非常规应答。
局限性
- 单中心回顾性分析,样本量有限(160例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors are an important tool in the therapeutic strategy against metastatic non-small cell lung cancer (NSCLC); however, radiological evaluation is challenging due to the emergence of atypical patterns of responses. Several evaluation criteria have been proposed, such as the Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1, immune -related RECIST (irRECIST) and iRECIST, but have not been systematically compared in a homogeneous population. PATIENTS AND METHODS: We conducted a monocentric retrospective analysis of consecutive advanced NSCLC patients treated with an anti-programmed cell death-1 or anti-program death-ligand 1. Response patterns and the discordance between RECIST 1.1, irRECIST and iRECIST guidelines were described, and associations of response patterns and clinical outcome were explored. RESULTS: Overall, 160 patients treated between February 2013 and October 2016 were included. Atypical responses were observed in 20 patients (13%), including eight pseudoprogressions (PsPDs) (5%) and 12 dissociated responses (8%). Thirteen of the 20 patients demonstrated clinical benefit. Per the RECIST 1.1, 37 patients (23%) showed an objective response or stable disease, and 123 patients (77%) exhibited progression. Eighty progressive patients were assessable for irRECIST and iRECIST: 15 patients were assessed differently; however, only three (3.8%) mismatches with a theoretical impact on the therapeutic decision were identified. Patients with PsPD or dissociated response had higher overall survival than patients with true progression. CONCLUSION: Atypical responses (PsPD/dissociated response) occurred in 13% of NSCLC patients under immune checkpoint inhibitors. Based on survival analyses, the RECIST 1.1 evaluation underestimated the benefit of immune checkpoint inhibitors in 11% of the progressive patients. Immune-related RECIST and iRECIST identified these unconventional responses, with a 3.8% discrepancy rate.
引用
- Tazdait M, Mezquita L, Lahmar J, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2017. PMID: 29182990. doi:10.1016/j.ejca.2017.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。